

# UNIVERSITY OF KENTUCKY BOARD OF TRUSTEES

B. Mark Evers, MD, Director, Markey Cancer Center

Peter N. Gilbert, Senior Vice President and Chief Operations Officer




# **CANCER CARE FOR THE COMMONWEALTH**

## Overview

- Kentucky challenges/burden of cancer
- Accomplishments/growth after National Cancer Institute (NCI) Designation
- “Destination site” for Kentuckians with cancer
- Leader in precision oncology treatments
- Future vision

## Kentucky Challenges



↑ **Smoking**

↑ **Obesity**

↑ **Infection**  
(HPV & HCV)

↑ **Poverty**

↑ **Cancer**

# Significant Burden of Cancer in Kentucky

**1<sup>st</sup>** in the nation  
in incidence rate  
for all cancer sites

Age-adjusted cancer incidence rates, 2010-2014				
	All Cancers	Lung	Colorectal	Cervical
U.S.	452.1	61.2	39.8	7.5
Kentucky <sup>†</sup>	521.1	95.3	50.0	8.7
<b>Appalachian Kentucky*</b>	<b>538.5</b>	<b>108.9</b>	<b>55.1</b>	<b>10.2</b>

<sup>†</sup> Kentucky vs. US; \*Appalachian vs. Non-Appalachian KY

**1<sup>st</sup>** in the nation  
in overall cancer  
mortality rate

Age-adjusted cancer mortality rates, 2010-2014				
	All Cancers	Lung	Colorectal	Cervical
U.S.	166.1	44.7	14.8	2.3
Kentucky <sup>†</sup>	201.5	69.6	17.2	2.8
<b>Appalachian Kentucky*</b>	<b>226.1</b>	<b>82.4</b>	<b>20.2</b>	<b>3.3</b>

**Cancer incidence and mortality are highest in Appalachia**


# Markey Cancer Center (MCC) NCI Designation Path

July 2013  
Awarded initial  
designation (5 years)

July 2018  
Successful renewal  
(5 years)

October 3, 2022  
Application for  
Comprehensive Status

February 7, 2023  
Site visit for  
Comprehensive Status



**July 12, 2013**  
MCC became the  
68<sup>th</sup> NCI-designated  
cancer center  
in the U.S.





## CANCER CARE FOR THE COMMONWEALTH


# What Achieving NCI Designation Has Meant To Kentucky



## MCC Impact


### MCC NETWORK SITES

~47% of all new cancer cases in Kentucky (2020) were directly or indirectly cared for by MCC




### CANCER CARE

Patients from  
**120/120**  
Kentucky counties  
in 2020






### CLINICAL TRIAL ACCRUALS

Individuals enrolled from  
**98/120**  
Kentucky counties  
in 2020





# MCC: The “Destination” Cancer Hospital for Kentucky



**RANKED IN THE TOP 50 BEST HOSPITALS FOR CANCER CARE FOR 6 STRAIGHT YEARS**

MCC: The “Destination” Cancer Hospital for Kentucky with Cancer



RANKED IN THE TOP 50 BEST HOSPITALS FOR  
CANCER CARE FOR 6 STRAIGHT YEARS

## Focus on Early Drug Development and Genomic Medicine

- MCC Precision Medicine Clinic (PMC) state-of-the art facility for complex biomarker-based trials and early drug development (opened Fall 2017)
- From 01/01/21 to 10/04/22, Markey's PMC provided:
  - 20 Investigator-initiated trials of novel agents or combinations
  - 42 Industry-sponsored trials of novel agents or combinations
  - 43 Cooperative group trials of novel agents or combinations through the NCI's Experimental Therapeutics Clinical Trials Network
- 326 patients enrolled to PMC Trials (2021-2022)
- 56% from Appalachia
- PMC is bringing national clinical trials to our patients and is the only place in Kentucky these trials are available



Chemo 6 mo

Crizotinib 18 mo


Ceritinib 16 mo

Clinical Trial 12 months

Bob's survival with stage 4 lung cancer = 52 months and counting

### The Story of Bob

- Bob is a 47-year-old who has never smoked. In 2013, he is diagnosed with lung adenocarcinoma with brain metastasis: **Life expectancy 12 months**
- Bob begins chemotherapy and radiation
  - November 20, 2013, FDA approves crizotinib for anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC
- In March 2014, he is found to have an EML4-ALK fusion and begins crizotinib
- In Jan. 2017, he progresses. MCC Molecular Tumor Board (MTB) recommends ceritinib, and he has another 16-month response to ceritinib
- In May 2019, he progresses again and the MCC MTB recommends participation in a clinical trial
- In 2020, he welcomes his first grandchild





## PMC patient volumes have tripled since opening in late 2017

- Chairs are overbooked most days of the week
- Patients routinely moved to overflow areas for infusions
- Will soon reach a point that we will not be able to handle the volume due to space constraints


## CANCER CARE FOR THE COMMONWEALTH

### Spaces Have Not Kept Up With Growth

New technologies and advances in science and exponential increases in patient volumes required Markey's footprint to expand to

**six different sites**

creating undue stress on our patients, burdening our staff and resulting in barriers to collaboration and efficiency



# Markey Cancer Center Advanced Ambulatory Building



- All cancer services co-located
- Multi-disciplinary clinics
- Laboratory
- Imaging
- State-of-the art expanded precision medicine clinic
- >400% increase in current precision medicine footprint



## Future Vision

- Achieving Comprehensive Cancer Center status by the National Cancer Institute
- Significantly improving patients' experiences by consolidating services into a new advanced ambulatory care center
- Continued growth to fulfill our critical mission of "Conquering Cancer in the Commonwealth"



A Cancer Center Designated by the  
National Cancer Institute



*Markey makes a difference.*



# QUESTIONS



# **PROPOSED SITE PLAN AND RENDERINGS**

## PROPOSED SITE PLAN

- Two buildings with connector
- Parking for first building and future building
- Property can accommodate buildings up to a combined 1,000,000 square feet




## RENDERING OF FIRST BUILDING WITH POTENTIAL SHELLED FLOORS





RENDERINGS OF FIRST BUILDING WITH POTENTIAL SHELLLED FLOORS WITH STACKING



Office of the President  
December 13, 2022

Members, Board of Trustees:

CONSTRUCT AMBULATORY FACILITY-UK HEALTHCARE AND  
CONSTRUCT STATE STREET MEDICAL FACILITIES – UK HEALTHCARE  
(CANCER TREATMENT CENTER/AMBULATORY OUTPATIENT CENTER)  
CONSTRUCTION PHASE CAPITAL PROJECT

Recommendation: that the Board of Trustees approve the initiation of the Construct Ambulatory Facility-UK HealthCare and Construct State Street Medical Facilities – UK HealthCare (Cancer Treatment Center/Ambulatory Surgery Center) Construction Phase capital project.

Background: Pursuant to Administrative Regulation 8:2, any capital project with an estimated scope of \$1,000,000 or more must be approved by the Board prior to initiation.

To better serve the Commonwealth, UK HealthCare has identified a need for a Cancer and Advanced Ambulatory Complex. On May 4, 2021, the Board approved the initiation of the design phase of this project. The design phase is underway, and it is now appropriate to begin the next phase and move forward with construction. The Cancer Treatment Center/Ambulatory Surgery Center project will include multiple clinical care buildings and structured parking with an anchor of approximately 260,000 square feet for cancer-specific services. Other services targeted for this location may include, but are not limited to, outpatient operating rooms, minor procedures, endoscopy, diagnostics and imaging services, pharmacy, retail, outpatient clinics, meeting spaces and necessary support spaces.

The revised combined scope of this project, authorized by the 2022 Session of the Kentucky General Assembly is \$500,000,000, which includes both the design and construction phases, and is well within the total legislative authorization of \$550,000,000. The project will be funded with agency funds. Pending Board approval, the university will report the combination of the two legislative authorizations and the transfer of funds from agency bonds to agency funds to the Capital Projects and Bond Oversight Committee.

---

Action taken:   ☐ Approved      ☐ Disapproved      ☐ Other\_\_\_\_\_

# QUESTIONS

